Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry.
The Journal of dermatological treatment（2022）
摘要
This real-life study demonstrated the effectiveness and good safety profile of all currently available IL-17 inhibitors.
更多查看译文
关键词
BIOREP,IL-17 inhibitors,Psoriasis,biological therapy,brodalumab,ixekizumab,real-world,registries,secukinumab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要